Re: Transition, Separation & Consultancy AgreementQuotient LTD • January 7th, 2020 • In vitro & in vivo diagnostic substances • Delaware
Thank you for your service to Quotient Limited (the “Company”). This letter, when fully executed, will constitute the Transition, Separation & Consultancy Agreement (“Agreement”) between you and the Company concerning the terms of your future retirement from employment with the Company.
QUOTIENT LIMITED FORM OF CHANGE OF CONTROL AGREEMENTForm of Change of Control Agreement • January 7th, 2020 • Quotient LTD • In vitro & in vivo diagnostic substances
THIS CHANGE OF CONTROL AGREEMENT (this “Agreement”), is made on this 7th day of January 2020, by and between QUOTIENT LIMITED, a public no par value limited liability company incorporated in Jersey, Channel Islands, with registered number 109886 (the “Company”) and Peter Buhler (the “Employee”).
EMPLOYMENT AGREEMENTEmployment Agreement • January 7th, 2020 • Quotient LTD • In vitro & in vivo diagnostic substances
This Employment Agreement (“Employment Agreement”) is entered into as of January 3, 2020, by and between Quotient Limited (“Employer”), or such affiliate of Employer as its Chairman of the Board of Directors of the Employer (the “Board”) may designate, and Peter Buhler (“Executive”) (collectively, the “Parties”).
